News and press releases: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 January 2018


Original post, click here

12/01/2018

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 January 2018

PRAC concludes one safety review

PRAC recommends suspending hydroxyethyl-starch solutions for infusion from the market

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) recommended the suspension of the marketing authorisations for hydroxyethyl-starch (HES) solutions for infusion across the European Union. These products are used as plasma volume replacement following acute blood loss, where treatment with alternative products known as ‘crystalloids’ alone is not considered to be sufficient.

The review was triggered by results from two studies indicating that HES-containing medicines were still being used in critically ill patients and those with sepsis and kidney injury despite restrictions introduced in 2013 to reduce the risks of kidney problems and deaths.

More information is provided in the public health communication below.

Agenda

Recommendation by PRAC

Ongoing referrals